Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Debt to Equity (2017 - 2023)

Historic Debt to Equity for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2023 value amounting to $0.0.

  • Autolus Therapeutics' Debt to Equity rose 15081.49% to $0.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.0, marking a year-over-year increase of 15081.49%. This contributed to the annual value of $0.0 for FY2022, which is 493.1% down from last year.
  • According to the latest figures from Q3 2023, Autolus Therapeutics' Debt to Equity is $0.0, which was up 15081.49% from $0.0 recorded in Q2 2023.
  • Autolus Therapeutics' 5-year Debt to Equity high stood at $0.0 for Q3 2023, and its period low was $0.0 during Q4 2022.
  • Over the past 3 years, Autolus Therapeutics' median Debt to Equity value was $0.0 (recorded in 2023), while the average stood at $0.0.
  • Within the past 5 years, the most significant YoY rise in Autolus Therapeutics' Debt to Equity was 15081.49% (2023), while the steepest drop was 661.0% (2023).
  • Autolus Therapeutics' Debt to Equity (Quarter) stood at $0.0 in 2021, then decreased by 4.93% to $0.0 in 2022, then skyrocketed by 320.77% to $0.0 in 2023.
  • Its Debt to Equity stands at $0.0 for Q3 2023, versus $0.0 for Q2 2023 and $0.0 for Q1 2023.